Calgary, Canada
Resverlogix Corp., a pioneering research-focused biotechnology company established in 2001 and headquartered in Canada, is advancing the treatment of chronic diseases through innovative epigenetic therapies. Its proprietary drug, apabetalone, discovered in 2006, leads a novel class of drugs that target bromodomain and extraterminal domain (BET) proteins, offering a promising approach to regulating gene expression.
This late-stage clinical biotech firm's primary focus is on addressing cardiovascular disease in patients with type 2 diabetes mellitus and low high-density lipoprotein. Apabetalone is currently in a Phase 3 clinical trial, BETonMACE, representing a significant opportunity to tap into the 70% of high-risk cardiovascular patients not fully addressed by existing statin treatments like Lipitor and Crestor.
Trading on the TSX under the symbol RVX since 2005, Resverlogix Corp. received its last investment, a Post-IPO Debt in May 2021, underscoring its ongoing financing momentum and the market's confidence in its innovative therapeutic solutions.
